Introduction and background
Diabetic hypertension is associated with microalbuminuria, which is a strong predictor for subsequent mortality. 1 Angiotensin-converting enzyme (ACE) inhibitors in some small studies 2, 3 have been shown to preferentially reduce albumin leakage. Recently the UKPDS has suggested that this is largely a blood pressure lowering effect and that ␤-blockers were as effective and more cost-effective. 4, 5 ASCOT will address most glycaemic and cardiovascular end points and safety issues but does not at present attempt to quantitate the microvascular endpoint of microalbuminuria either at baseline or during follow-up in the potentially large numbers of type 2 diabetic hypertensives. Over 80% of diabetic hypertensives will need treatment with two or more antihypertensive agents to reach a flat target of 130/80 mm Hg, 3 so both limbs of ASCOT should provide sufficient patients on either ␤-blocker and diuretic, or calcium (Ca) channel blocker plus ACE inhibitors, to provide sufficient numbers to evaluate using albumin/creatinine ratio whether there is any difference in progression of microalbuminuria between the two treatment regimens.
Objectives
We propose to study the albumin/creatinine ratio in a cohort of 300 patients with diabetic hypertension in the ASCOT study by measuring the early morning albumin/creatinine ratio as the primary end point. Many studies in diabetic and non-diabetic proteinuric and microalbuminuric patients have suggested that the relatively simple device of taking the urine in a spot sample and then correcting for creatinine (as a measure of concentration) provides a user-friendly and accurate measure of microalbuminuria. This was, for technical reasons, not part of the UKPDS study, which relied on a clinic random urinary albumin estimate without correction for creatinine on an individual basis. The very large numbers achieved in the UKPDS allowed the study to use this spot albumin concentration as a measure of albuminuria, but its variability makes it of little use in clinical practice where ratio is increasingly used.
Study methods/design
Patients with type 2 diabetes and hypertension in the ASCOT study in our centre will be invited to provide a sample of urine and this will be measured for albumin/creatinine ratio. These samples will be taken at baseline and for the subsequent 5 years, at 6 monthly intervals to accord with study visits. A sub-group of patients (n = 100) will be asked to provide a simultaneous early morning urine and spot clinic urine to assess variability and whether there were any differences between the early morning first void which should be close to the overnight albumin excretion rate (AER) and the daytime spot clinic value.
While the UKPDS used large numbers (n = 758 with 545 remaining compliant) the methodology of assessing albumin excretion relied only on a spot albumin concentration. 4 The use of a spot albumin/creatinine ratio should give results comparable to the standard method of using a timed overnight AER. 6, 7 Using the data provided by a recent study in type 2 diabetic patients which compared two hypertensive regimens 2 and working on a null hypothesis of a percentage change with time in the progression of the albumin/creatinine ratio between the group on the ␤-blocker compared to the group on ACE inhibitor, we have estimated that about 300 type 2 diabetic hypertensive patients would need to be randomised. A sub-study size of 300 would permit the detection of a between-treatment difference
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Journal of Human Hypertension in albumin/creatinine ratio of 1.0 mg/mmol which was determined as clinically important with a 90% power at a 5% significant level. These assumptions are made on the basis that the albumin/creatinine ratio has a close correlation with UAER of 0.932. 7 The sub-study has the approval of Coventry and Warwickshire Research and Ethics Committees. The sub-study will aim to recruit 300 hypertensive diabetic subjects to allow for at least 120 in each group to be on either ACE inhibitor or ␤-blocker to allow for drop out over the first 2 years. Interim analysis will take place after 12 months. Subject recruitment, inclusion and exclusion criteria and methodology will follow the main ASCOT protocol.
Discussion
Perhaps through successful marketing rather than through an evidence-base there is a widely held view amongst practitioners in the UK that ACEinhibitors are the treatment of choice in the diabetic hypertensive and mandatory for those with microalbuminuria. The UKPDS study 4, 5 in type 2 hypertensive patients, some of whom had microalbuminuria, concluded that the choice of agent was not important and that what mattered was the effectiveness of the blood pressure lowering. This study had considerable power as it involved about 400 diabetic hypertensive patients in each of the two limbs (␤-blockers and ACE inhibitors) and its assessment of the progression of microvascular disease with retinopathy assessed by photography is impressive. For technical reasons the UKPDS did not assess microalbuminuria with correction for creatinine so that the spot albumin concentrations recorded are difficult to equate with the definition of microalbuminuria based on timed urine collections.
More recently it has become part of accepted clinical practice in diabetes care to use an albumin/creatinine ratio which allows the use of a spot urine collection which is corrected for any variability due to the concentration of the urine. This test has been shown to be significantly superior to albumin concentration particularly when sex and age-specific discriminator valves are employed. 6 Compared to a timed albumin excretion rate the albumin/creatinine ratio performed with 94% sensitivity and 93% specificity in the prediction of microalbuminuria. 6 This methodology has been applied successfully in the long-term follow-up of patients and shown to be a precise indicator in the progression of disease on non-diabetic patients with chronic nephropathies. 7 The ASCOT study should provide hard evidence as to which of the limbs (␤-blocker and diuretic or Ca-channel blocker and ACE inhibitor) confers the best cardiovascular protection in diabetic patients and whether this is entirely a function of blood pressure lowering itself. We aim to study a small group of hypertensive diabetics using the albumin/ creatinine ratio to follow the progression of this marker and to evaluate its relationship to the treatment with ␤-blocker or ACE-inhibitor and its relationship to cardiovascular outcome.
